diethyl 2-chloro-3-oxopentanedioate | 476415-70-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: diethyl 2-chloro-3-oxopentanedioate
• 英文别名: 2-Chlor-3-oxo-pentandisaeure-diethylester；2-chloro-3-oxopentanedioic acid diethyl ester；2-Chloro-3-oxo-pentanedioic acid diethyl ester
• CAS: 476415-70-0
• 化学式: C₉H₁₃ClO₅
• 分子量: 236.652
• InChiKey: DRXLGCZDLWMAPF-UHFFFAOYSA-N

物化性质

• 沸点：
  146.5-147.5 °C(Press: 12 Torr)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diethyl 2-chloro-3-oxopentanedioate 在 乙酸酐 、 sodium hydroxide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 16.0h， 生成 4-[2-(2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-2-(morpholin-4-yl)-1,3-thiazole-5-carboxylic acid
  参考文献：
  名称：

  作为有效和选择性PI3Kβ抑制剂的新型4-（2-（吲哚-1-基）-2-氧代乙基）-2-吗啉基噻唑-5-羧酸和酰胺衍生物的制备和优化

  摘要：

  在我们不断努力确定和开发新型靶向癌症治疗方法的过程中，已经确定了一种新型的对PI3Kβ具有活性的吗啉代-噻唑支架。这封信报告了该化合物类别的优化，以开发具有合适药理特性的PI3Kβ同工型选择性抑制剂。

  DOI：

  10.1016/j.bmcl.2014.02.004
• 作为产物：
  描述：

  1,3-丙酮二羧酸二乙酯 在 磺酰氯 作用下， 以 二氯甲烷 为溶剂， 以100%的产率得到diethyl 2-chloro-3-oxopentanedioate
  参考文献：
  名称：

  WO2008/76562

  摘要：

  公开号：

文献信息

• Synthesis of 2-chloro-3-oxoesters by reaction of the dianion of ethyl 2-chloroacetoacetate with electrophiles
  作者：Verena Specowius、Thomas Rahn、Muhammad Adeel、Stefanie Reim、Holger Feist、Ashot S. Saghyan、Peter Langer

  DOI：10.1007/s00706-012-0897-z

  日期：2013.5

  Abstract2-Chloro-3-oxoalkanoates and related molecules were prepared by regioselective reaction of the dianion of ethyl 2-chloroacetoacetate with alkyl halides and other electrophiles. Graphical Abstract

  摘要通过2-氯乙酰乙酸乙酯的二价阴离子与烷基卤化物和其他亲电试剂的区域选择性反应制备2-氯-3-氧代链烷酸酯和相关分子。 图形概要
• 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS
  申请人：Gardinier Kevin Matthew

  公开号：US20100069352A1

  公开（公告）日：2010-03-18

  The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein “ - - - ” is absent or is optionally a bond; q is 1 or 2; R 1 is independently selected from hydrogen, —C 1 -C 2 alkyl, halo, hydroxy, —C 1 -C 2 haloalkyl, —C 1 -C 3 alkoxy, cyano, —O—C 3 -C 4 cycloalkyl, and —OC 1 -C 2 haloalkyl; R 2 is selected from the group consisting of hydrogen, —C 1 -C 3 alkyl, hydroxy, —C 1 -C 3 alkoxy, cyano, —C 1 -C 2 haloalkyl, —OC 1 -C 2 haloalkyl, and halo; R 3 is selected from the group consisting of hydrogen, —C 1 -C 4 alkyl, —C 2 -C 4 haloalkyl, —C 2 -C 4 alkylOH, —C 3 -C 6 cycloalkyl, —CH 2 C 3 -C 6 cycloalkyl, —C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —C(O)C 1 -C 4 alkyl, —C(O)C 1 -C 4 haloalkyl, —CH 2 -thiazole, phenyl, benzyl, tetrahydrothiopyranyl, and tetrahydropyranyl, wherein the cycloalkyl, tetrahydrothiopyranyl, tetrahydropyranyl and thiazolyl group is optionally substituted with one or two groups independently selected from the group consisting of halo, hydroxy, C 1 -C 2 alkyl, and —C 1 -C 2 haloalkyl; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof, useful in the treating, preventing or ameliorating of symptoms associated with obesity and related diseases.

  本发明涉及一种公式I的黑色素浓集激素拮抗剂化合物：其中“- - -”不存在或者可选为一根键；q为1或2；R1独立选择自氢、—C1-C2烷基、卤素、羟基、—C1-C2卤代烷基、—C1-C3烷氧基、氰基、—O—C3-C4环烷基和—OC1-C2卤代烷基；R2选择自氢、—C1-C3烷基、羟基、—C1-C3烷氧基、氰基、—C1-C2卤代烷基、—OC1-C2卤代烷基和卤素的群；R3选择自氢、—C1-C4烷基、—C2-C4卤代烷基、—C2-C4烷基羟基、—C3-C6环烷基、—CH2C3-C6环烷基、—C2-C4烷氧基—C1-C4烷基、—C（O）C1-C4烷基、—C（O）C1-C4卤代烷基、—CH2-噻唑基、苯基、苄基、四氢噻吩基和四氢吡喃基，其中环烷基、四氢噻吩基、四氢吡喃基和噻唑基可选地被一到两个独立选择自卤素、羟基、C1-C2烷基和—C1-C2卤代烷基的基团取代；或其药学上可接受的盐、对映异构体、非对映异构体或其混合物，用于治疗、预防或缓解与肥胖和相关疾病相关的症状。
• 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists
  申请人：Eli Lilly and Company

  公开号：US08049013B2

  公开（公告）日：2011-11-01

  The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein “-----” is absent or is optionally a bond; q is 1 or 2; R1 is independently selected from hydrogen, —C1-C2 alkyl, halo, hydroxy, —C1-C2 haloalkyl, —C1-C3 alkoxy, cyano, —O—C3-C4 cycloalkyl, and —OC1-C2 haloalkyl; R2 is selected from the group consisting of hydrogen, —C1-C3 alkyl, hydroxy, —C1-C3 alkoxy, cyano, —C1-C2 haloalkyl, —OC1-C2 haloalkyl, and halo; R3 is selected from the group consisting of hydrogen, —C1-C4 alkyl, —C2-C4 haloalkyl, —C2-C4 alkylOH, —C3-C6 cycloalkyl, —CH2C3-C6 cycloalkyl, —C2-C4 alkyl-O—C1-C4 alkyl, —C(O)C1-C4 alkyl, —C(O)C1-C4 haloalkyl, —CH2-thiazole, phenyl, benzyl, tetrahydrothiopyranyl, and tetrahydropyranyl, wherein the cycloalkyl, tetrahydrothiopyranyl, tetrahydropyranyl and thiazolyl group is optionally substituted with one or two groups independently selected from the group consisting of halo, hydroxy, C1-C2 alkyl, and —C1-C2 haloalkyl; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof, useful in the treating, preventing or ameliorating of symptoms associated with obesity and related diseases.

  本发明涉及一种公式I的黑素浓集素拮抗剂化合物：其中“-----”不存在或可选为键；q为1或2；R1独立选择自氢、—C1-C2烷基、卤素、羟基、—C1-C2卤代烷基、—C1-C3烷氧基、氰基、—O—C3-C4环烷基和—OC1-C2卤代烷基；R2选择自羟基、—C1-C3烷基、—C1-C3烷氧基、氰基、—C1-C2卤代烷基、—OC1-C2卤代烷基和卤素的群；R3选择自氢、—C1-C4烷基、—C2-C4卤代烷基、—C2-C4烷基羟基、—C3-C6环烷基、—CH2C3-C6环烷基、—C2-C4烷氧基—C1-C4烷基、—C(O)C1-C4烷基、—C(O)C1-C4卤代烷基、—CH2-噻唑基、苯基、苄基、四氢噻吩基和四氢吡喃基，其中环烷基、四氢噻吩基、四氢吡喃基和噻唑基可选地用一个或两个从卤素，羟基，C1-C2烷基和—C1-C2卤代烷基中独立选择的基取代；或其药学上可接受的盐、对映异构体、顺反异构体或混合物，用于治疗、预防或缓解与肥胖和相关疾病相关的症状。
• Beyer; Kreutzberger, Chemische Berichte, 1951, vol. 84, p. 482,483
  作者：Beyer、Kreutzberger

  DOI：——

  日期：——
• 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS
  申请人：Eli Lilly & Company

  公开号：EP2089397B1

  公开（公告）日：2012-08-29